American Portfolios Advisors Zynerba Pharmaceuticals, Inc. Transaction History

American Portfolios Advisors

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Mar 22, 2023	BUY	$3.83 - $5.98 $153 - $239	40 New	40 $212,000
Q1 2020 Mar 24, 2023	BUY	$2.9 - $6.16 $1,241 - $2,636	428 New	428 $1.64 Million
Q4 2019 Mar 24, 2023	BUY	$5.61 - $8.57 $2,401 - $3,667	428 New	428 $2.59 Million
Q3 2019 Mar 24, 2023	SELL	$7.56 - $15.44 $1,126 - $2,300	-149 Reduced 25.82%	428 $3.24 Million
Q2 2019 Mar 24, 2023	BUY	$5.4 - $15.5 $3,115 - $8,943	577 New	577 $7.82 Million
Q4 2018 Mar 24, 2023	BUY	$2.89 - $7.91 $1,236 - $3,385	428 New	428 $1.27 Million
Q1 2018 Mar 24, 2023	BUY	$8.49 - $13.46 $1,825 - $2,893	215 New	215 $1.87 Million

774K

Ticker ZYNE
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 45,753,100
Description
Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically-produced cannabidiol formulated as a permeation-enhanced gel for t...

Get notified when there are updates to the investment portfolio of American Portfolios Advisors, based on Form 13F filings with the SEC.

Stay updated on American Portfolios Advisors with notifications on news.